JP2005510521A - 生体適合性ポリマーブレンドおよびその使用 - Google Patents

生体適合性ポリマーブレンドおよびその使用 Download PDF

Info

Publication number
JP2005510521A
JP2005510521A JP2003543576A JP2003543576A JP2005510521A JP 2005510521 A JP2005510521 A JP 2005510521A JP 2003543576 A JP2003543576 A JP 2003543576A JP 2003543576 A JP2003543576 A JP 2003543576A JP 2005510521 A JP2005510521 A JP 2005510521A
Authority
JP
Japan
Prior art keywords
polymer
poly
sustained release
poloxamer
biocompatible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003543576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005510521A5 (enExample
Inventor
コンスタンティーノ，ヘンリー，アール．
トレーシー，マーク，エイ．
ウォード，ケビン，エル．
ネルソン，ウェンディ，ダブリュ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Controlled Therapeutics Inc
Original Assignee
Alkermes Controlled Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Controlled Therapeutics Inc filed Critical Alkermes Controlled Therapeutics Inc
Publication of JP2005510521A publication Critical patent/JP2005510521A/ja
Publication of JP2005510521A5 publication Critical patent/JP2005510521A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003543576A 2001-11-12 2002-11-12 生体適合性ポリマーブレンドおよびその使用 Pending JP2005510521A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33286801P 2001-11-12 2001-11-12
PCT/US2002/036365 WO2003041689A1 (en) 2001-11-12 2002-11-12 Biocompatible polymer blends and uses thereof

Publications (2)

Publication Number Publication Date
JP2005510521A true JP2005510521A (ja) 2005-04-21
JP2005510521A5 JP2005510521A5 (enExample) 2006-01-05

Family

ID=23300202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003543576A Pending JP2005510521A (ja) 2001-11-12 2002-11-12 生体適合性ポリマーブレンドおよびその使用

Country Status (6)

Country Link
US (1) US7282216B2 (enExample)
EP (1) EP1443907A1 (enExample)
JP (1) JP2005510521A (enExample)
AU (1) AU2002343681B2 (enExample)
CA (1) CA2466998A1 (enExample)
WO (1) WO2003041689A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511622A (ja) * 2012-03-30 2015-04-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ミクロスフィア組成物、その調製方法及び用途

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
DK1392254T3 (da) 2001-04-20 2007-07-02 Univ British Columbia Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862535B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques
FR2862541B1 (fr) * 2003-11-21 2007-04-20 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
WO2005079856A1 (en) * 2004-02-23 2005-09-01 The University Of British Columbia Drug delivery compositions comprising hydrophobic polymers and amphipathic molecules
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US20060198868A1 (en) * 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
US20060149363A1 (en) * 2005-01-06 2006-07-06 Scimed Life Systems, Inc. Optimally expanded, collagen sealed ePTFE graft with improved tissue ingrowth
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US8192731B2 (en) * 2005-10-25 2012-06-05 Loctite (R&D) Limited Thickened cyanoacrylate compositions
WO2008157540A1 (en) * 2007-06-20 2008-12-24 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
KR20100056479A (ko) 2007-07-25 2010-05-27 바이오렉스 쎄라퓨틱스, 인코포레이티드 제어 방출 인터페론 약물 제품 및 이를 사용한 ｈｃｖ 감염의 치료
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
AU2010234916A1 (en) * 2009-03-30 2011-10-13 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
US8883208B2 (en) * 2009-04-08 2014-11-11 Surmodics, Inc. Particles for delivery of nucleic acids and related devices and methods
EP2416762A2 (en) * 2009-04-08 2012-02-15 SurModics, Inc. Controlled release devices and methods for delivery of nucleic acids
MX2012012001A (es) 2010-04-16 2013-05-01 Apatech Ltd Biomaterial.
US9173978B2 (en) 2010-09-22 2015-11-03 Ethicon, Inc. Bioabsorbable polymeric compositions, processing methods, and medical devices therefrom
WO2013082503A1 (en) * 2011-12-01 2013-06-06 Flow Pharma, Inc. Peptide particle formulation
WO2013086419A1 (en) * 2011-12-09 2013-06-13 California Institute Of Technology Polymer scaffolds and their use in the treatment of vision loss
US20150044147A1 (en) * 2013-02-18 2015-02-12 King Abdullah International Medical Research Center Composition for management of periodontal disease
EP2986323A4 (en) * 2013-04-16 2016-10-19 Univ Case Western Reserve NEUTRALLY LOADED SYNTHETIC BLOOD PLATES TO REDUCE A COMPLEMENT REACTION
US9775929B2 (en) * 2014-04-14 2017-10-03 University Of Maryland College Park Solution blow spun polymer fibers, polymer blends therefor and methods and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
JP4979843B2 (ja) 1995-03-10 2012-07-18 ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 微粒子の形のポリペプチド含有投薬形
US5709852A (en) * 1995-12-05 1998-01-20 Basf Corporation Ethylene oxide/propylene oxide/ethylene oxide (EO/PO/EO) triblock copolymer carrier blends
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
WO2001041735A2 (en) 1999-12-07 2001-06-14 Amgen Inc. Thermosensitive biodegradable hydrogels based on low molecular weight pluronics
US6296842B1 (en) * 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511622A (ja) * 2012-03-30 2015-04-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ミクロスフィア組成物、その調製方法及び用途

Also Published As

Publication number Publication date
WO2003041689A1 (en) 2003-05-22
EP1443907A1 (en) 2004-08-11
AU2002343681B2 (en) 2006-07-06
CA2466998A1 (en) 2003-05-22
US7282216B2 (en) 2007-10-16
US20030133980A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
US7282216B2 (en) Biocompatible polymer blends and uses thereof
AU2002343681A1 (en) Biocompatible polymer blends and uses thereof
US6479065B2 (en) Process for the preparation of polymer-based sustained release compositions
US6455074B1 (en) Methods for fabricating polymer-based controlled release devices
US6296842B1 (en) Process for the preparation of polymer-based sustained release compositions
AU772910B2 (en) Method of producing submicron particles of a labile agent
AU2002244314B2 (en) Modification of the sustained release profile
EP0644771B2 (en) Erythropoietin drug delivery system
US20040057996A1 (en) Sustained-release preparation
DK1742616T3 (en) The microsphere-discharge-system for the prolonged delivery and methods of making and using the same
JP2003512316A (ja) 生物学的活性薬剤のサブミクロン粒子の製造方法
AU2002244314A1 (en) Modification of the sustained release profile
WO2004103342A2 (en) Injectable sustained release compositions
JP2006505562A (ja) 持続放出組成物の放出プロフィールの調節方法
CN1438881A (zh) 胰岛素控释制剂及其方法
WO1998007412A1 (en) Controlled release microparticles with a hydrophobic material
US20060269602A1 (en) Method of modifying the release profile of sustained release compositions
Ravivarapu et al. Biodegradable polymeric delivery systems
JP3761594B2 (ja) 徐放性製剤の製造法
WO2001058428A1 (en) Method of preparing a sustained release composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090521

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091015